伊布替尼-话题@MedSci

#伊布替尼#

88篇内容 | 3983人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2092794, encodeId=46e92092e949f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a><a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>用于儿童慢性 <a href='/topic/show?id=00a18335de' target=_blank style='color:#2F92EE;'>#GVHD#</a> 患者。<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>每年要批准大量的<a href='/topic/show?id=60c232154fc' target=_blank style='color:#2F92EE;'>#创新药物#</a>，非常值得关注, objectTitle=FDA 批准伊布替尼用于儿童慢性 GVHD 患者, objectType=article, longId=736912, objectId=3174e369127e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220824/1661347590610_5579292.jpg, objectUrl=/article/show_article.do?id=3174e369127e, replyNumber=0, likeNumber=144, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3174e369127e, moduleTitle=FDA 批准伊布替尼用于儿童慢性 GVHD 患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3174e369127e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288785, encodeId=e4cf1288e8549, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=FDA 批准伊布替尼用于儿童慢性 GVHD 患者, objectType=article, longId=736912, objectId=3174e369127e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3174e369127e, replyNumber=0, likeNumber=113, createdTime=2022-08-26, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3174e369127e, moduleTitle=FDA 批准伊布替尼用于儿童慢性 GVHD 患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3174e369127e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288784, encodeId=96601288e8451, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, objectType=article, longId=731593, objectId=2592e3159385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2592e3159385, replyNumber=0, likeNumber=147, createdTime=2022-07-09, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2592e3159385, moduleTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2592e3159385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288783, encodeId=37021288e8314, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=82, createdTime=2022-01-17, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288782, encodeId=51a51288e8207, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, objectType=article, longId=218715, objectId=800e218e15c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=800e218e15c8, replyNumber=0, likeNumber=84, createdTime=2021-10-18, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=800e218e15c8, moduleTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=800e218e15c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288781, encodeId=b14f1288e817e, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=113, createdTime=2021-10-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288780, encodeId=30241288e801f, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Heart：伊布替尼与高血压的关系, objectType=article, longId=213858, objectId=a92521385881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92521385881, replyNumber=0, likeNumber=145, createdTime=2021-07-08, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92521385881, moduleTitle=Heart：伊布替尼与高血压的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92521385881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288779, encodeId=a38b1288e7900, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点, objectType=article, longId=206320, objectId=9bfb2063201f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bfb2063201f, replyNumber=0, likeNumber=70, createdTime=2021-01-29, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bfb2063201f, moduleTitle=阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bfb2063201f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288778, encodeId=f7d01288e780e, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=67, createdTime=2020-05-03, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288777, encodeId=98d31288e77d4, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, objectType=article, longId=193097, objectId=69fe19309e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69fe19309e48, replyNumber=0, likeNumber=86, createdTime=2020-04-29, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69fe19309e48, moduleTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69fe19309e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288776, encodeId=8e291288e7602, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Mabruxixafor联合伊布替尼治疗华氏巨球蛋白血症：已开始Ib期临床试验, objectType=article, longId=185518, objectId=16b01855189a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16b01855189a, replyNumber=0, likeNumber=58, createdTime=2020-01-02, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16b01855189a, moduleTitle=Mabruxixafor联合伊布替尼治疗华氏巨球蛋白血症：已开始Ib期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16b01855189a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288775, encodeId=9b091288e758d, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, objectType=article, longId=179896, objectId=248a1e9896b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=248a1e9896b0, replyNumber=0, likeNumber=57, createdTime=2019-09-24, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=248a1e9896b0, moduleTitle=伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=248a1e9896b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288774, encodeId=043d1288e743c, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病, objectType=article, longId=176645, objectId=15ff1e664561, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ff1e664561, replyNumber=0, likeNumber=68, createdTime=2019-08-03, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ff1e664561, moduleTitle=NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ff1e664561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288773, encodeId=405c1288e7383, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=CHMP对伊布替尼在欧洲两种适应症扩大持积极态度, objectType=article, longId=174499, objectId=df1f1e44992a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df1f1e44992a, replyNumber=0, likeNumber=68, createdTime=2019-07-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df1f1e44992a, moduleTitle=CHMP对伊布替尼在欧洲两种适应症扩大持积极态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df1f1e44992a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288772, encodeId=be961288e72f2, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著, objectType=article, longId=166158, objectId=fd4816615892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd4816615892, replyNumber=0, likeNumber=54, createdTime=2019-05-17, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd4816615892, moduleTitle=BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd4816615892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288771, encodeId=f2a41288e71cb, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=专家“亿”周谈—— J CLIN ONCOL：伊布替尼单药治疗症状型/初治型华氏巨球蛋白血症的全新突破, objectType=article, longId=164128, objectId=3027164128e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3027164128e1, replyNumber=0, likeNumber=50, createdTime=2019-04-14, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3027164128e1, moduleTitle=专家“亿”周谈—— J CLIN ONCOL：伊布替尼单药治疗症状型/初治型华氏巨球蛋白血症的全新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3027164128e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288770, encodeId=4c771288e7054, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, objectType=article, longId=159161, objectId=a1f815916100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f815916100, replyNumber=0, likeNumber=73, createdTime=2019-01-31, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f815916100, moduleTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f815916100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288769, encodeId=e5c91288e69b7, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM：未经治的慢淋白血病老年患者：伊布替尼方案vs化学免疫疗法, objectType=article, longId=158716, objectId=a075158e1652, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a075158e1652, replyNumber=0, likeNumber=55, createdTime=2019-01-25, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a075158e1652, moduleTitle=NEJM：未经治的慢淋白血病老年患者：伊布替尼方案vs化学免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a075158e1652)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288768, encodeId=9b311288e685e, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, objectType=article, longId=157519, objectId=39d615e51935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d615e51935, replyNumber=0, likeNumber=43, createdTime=2019-01-09, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d615e51935, moduleTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d615e51935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288767, encodeId=187e1288e6757, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=NEJM：伊布替尼用于老年慢性淋巴细胞白血病, objectType=article, longId=155107, objectId=5b1a15510e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b1a15510e83, replyNumber=0, likeNumber=74, createdTime=2018-12-06, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b1a15510e83, moduleTitle=NEJM：伊布替尼用于老年慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b1a15510e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#FDA批准##伊布替尼#用于儿童慢性 #GVHD# 患者。#FDA#每年要批准大量的#创新药物#，非常值得关注

FDA 批准伊布替尼用于儿童慢性 GVHD 患者

2022-10-10

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

FDA 批准伊布替尼用于儿童慢性 GVHD 患者

2022-08-26

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）

2022-07-09

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-01-17

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化

2021-10-18

仁者大医 (审核中...)

前往app查看评论内容

#伊布替尼#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2021-10-07

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Heart：伊布替尼与高血压的关系

2021-07-08

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点

2021-01-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-05-03

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究

2020-04-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Mabruxixafor联合伊布替尼治疗华氏巨球蛋白血症：已开始Ib期临床试验

2020-01-02

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼治疗B细胞恶性肿瘤中国专家共识（2019年版）

2019-09-24

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病

2019-08-03

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

CHMP对伊布替尼在欧洲两种适应症扩大持积极态度

2019-07-01

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著

2019-05-17

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

专家“亿”周谈—— J CLIN ONCOL：伊布替尼单药治疗症状型/初治型华氏巨球蛋白血症的全新突破

2019-04-14

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

2019-01-31

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM：未经治的慢淋白血病老年患者：伊布替尼方案vs化学免疫疗法

2019-01-25

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则

2019-01-09

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

NEJM：伊布替尼用于老年慢性淋巴细胞白血病

2018-12-06

科室
- - 订阅+
  - 更多科室
工具
服务